Comment on CMS-2026-2047-0002

Summary: Indivior Pharmaceuticals, Inc. opposes the "significant impairment" requirement in the proposed rule, arguing it unnecessarily narrows the medical frailty exemption for individuals with substance use disorders (SUDs). The company argues that this requirement could disrupt Medicaid coverage for people in recovery and recommends that a documented SUD diagnosis alone should be sufficient to qualify for the exemption.